IRVINE, CA and AMSTERDAM, THE NETHERLANDS – Agendia, Inc. and several European partners have received a $6.8 million European Commission grant to study targeted therapies for colorectal cancer (CRC). The grantees will test therapies matched to the molecular subtype of each patient’s tumor, to see if they are more effective than current therapies not keyed to a tumor’s subtype. Agendia technology will be used to determine the molecular subtypes of the cancers studied.
The title of the project is “Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer,” abbreviated as “MoTriColor.” The four-year project will perform phase II studies across Europe for the treatment of molecular subgroups of CRC patients with advanced disease.
“This grant recognizes the value of Agendia’s ability to identify the molecular subtypes that are a central part of precision medicine to treat cancer,” said Mark Straley, Agendia’s CEO.
“Our technology has already demonstrated the value of this approach for breast cancer,” said Rene Bernards, Agendia’s Chief Scientific Officer. “The MoTriColor study is expected to show that a similar therapeutic strategy can benefit colon cancer patients.”
Including Agendia, the MoTriColor project encompasses 10 institutions in the Netherlands, Belgium, Spain and Italy. Two major pharmaceutical companies are expected to support the research.
Like breast cancer, CRC is increasingly seen not as a single disease but rather a group of diseases with distinct molecular subtypes. The MoTriColor research is particularly aimed at CRC patients with a poor prognosis. Roughly 40-50% of these patients worldwide, including about 40,000 European patients, have one of the three molecular subtypes matched to targeted therapies in the MoTriColor project and thus could benefit from the study’s results.
About Agendia:
Agendia is a privately held, leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer and colorectal cancer tests were developed using an unbiased gene selection by analyzing the complete human genome. Our offerings include the FDA-cleared MammaPrint® FFPE as well as BluePrint®, a molecular subtyping assay that provides deeper insight leading to more clinically actionable breast cancer biology, and TargetPrint®, a breast cancer ER/PR/HER2 expression assay. These tests can help physicians assess a patient’s individual risk for metastasis – that is, which patients are more sensitive to chemo, hormonal, or combination therapy, and which patients may not require these treatments and which patients may be treated with other, less arduous and costly methods.
In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology. It is also a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit
Liz Dowling (Medical & Consumer Media)
Dowling & Dennis Public Relations
Léon Melens
SPJ Financiële & Corporate Communicatie
+31 20 647 81 81